Business Wire

CA-NTT

19.5.2020 00:02:12 CEST | Business Wire | Press release

Share
The University of California, Berkeley Partners with NTT to Accelerate Smart Technologies

The University of California, Berkeley and NTT Corporation (NTT) today announced a connected campus pilot project that will leverage technology to transform the UC Berkeley Parking and Transportation Department by analyzing patterns, easing traffic congestion and increasing pedestrian safety in the Bancroft Way area of campus.

The pilot will incorporate NTT’s Accelerate Smart data platform and Dell Technologies’ modular data center infrastructure for edge deployments of high-definition optical sensors and IoT devices that monitor traffic-related issues. These smart technologies will provide data to facilitate enhanced traffic management and mobility. As a first step in their “Connected Campus” initiative, UC Berkeley will leverage vehicle counting and classification to make informed decisions and develop specific solutions.

“At Berkeley, we are always trying to stay on top of emerging trends in parking and transportation, and by incorporating smart technologies, our campus can serve as a test bed for new technologies that can be put into operation immediately,” said Seamus Wilmot, Director of Parking and Transportation, UC Berkeley. “Our partnership with NTT and Dell Technologies makes us more digitally-enabled and provides a better understanding for alleviating the root causes of traffic issues. These technologies will help us solve how to manage the curb space at an area that has been challenging for our students, faculty, staff and partners.”

As part of the pilot, NTT and Dell Technologies will implement smart IoT, safety and security innovations that support UC Berkeley’s Parking and Transportation Department, such as real-time alerts and traffic statistics that improve predictions and outcomes. With quantifiable data, UC Berkeley can curb congestion caused by events, ride share traffic, delivery vehicles and transit operations.

The pilot program is designed to provide automated deployment and operation of necessary information and communications technology (ICT) resources from devices and networks to the cloud. The solution will ensure UC Berkeley can focus on improving traffic conditions through analysis and process more efficiently without worrying about ICT deployment and optimization issues.

“This traffic management pilot program begins UC Berkeley’s transformation to a Connected Campus,” said Akira Shimada, Senior Executive Vice President, NTT. “Connected Campuses of the future will offer endless possibilities—for safety, crowd control, traffic and facilities management. UC Berkeley is just getting started, but as a world renowned forward-thinking academic and research University, they see the potential to improve the campus experience and operations using data and smart technologies.”

NTT, along with its operating companies, will deploy its Accelerate Smart solution, which is a secure, distributed network as a platform solution built on NTT’s innovative Cognitive Foundation™ architecture. It enables remote creation, management and operation of information and communications technology resources, from devices and networks to the cloud. It also incorporates hyperconverged infrastructure and IoT gateways from Dell Technologies, as well as virtualization software hosting predictive analytics applications from VMware.

“When we leverage longstanding relationships with great partners like NTT, our joint customers can transform the way they do business,” said Denise Millard, Senior Vice President, Global Alliances, Dell Technologies. “Together we are able to provide customers like UC Berkeley with new tools to leverage data in meaningful ways and make decisions faster to ultimately improve the experience of those on campus.”

Following the initial pilot, UC Berkeley, NTT and Dell Technologies plan to evaluate viability to extend the pilot and potentially add additional locations and use cases on campus. To learn more about the NTT accelerating smart solutions, visit NTT DATA’s website and watch the Accelerate Smart case study with the city of Las Vegas on YouTube .

About NTT

NTT believes in resolving social issues through our business operations by applying technology for good. We help clients accelerate growth and innovate for current and new business models. Our services include digital business consulting, technology and managed services for cybersecurity, applications, workplace, cloud, data center and networks all supported by our deep industry expertise and innovation.

As a top 5 global technology and business solutions provider, our diverse teams operate in 88 countries and regions and deliver services to over 190 of them. We serve 85% of Fortune Global 100 companies and thousands of other clients and communities around the world.
For more information on NTT, visit www.global.ntt/ .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 09:10:00 CEST | Press release

LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The

“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 09:00:00 CEST | Press release

Giant Hatsune Miku Returns to Light Up Tokyo’s Night! The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the

Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 09:00:00 CEST | Press release

Accomplished life sciences leader with a proven track record of driving successful development of novel therapeutics, joins Mosaic to guide its next phase of growthAllison brings three decades of drug development, board and executive leadership experience to support Mosaic’s transition towards a clinical-stage company Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 year

TOHKnet and Adtran conduct Japan’s first 50G PON trial on a live network4.8.2026 09:00:00 CEST | Press release

News summary: TOHKnet is exploring next-generation PON to meet enterprise demand while maintaining continuity across its regional fiber network Using Adtran technology, the trial validated 50G PON, XGS-PON and EPON operating together on a single fiber network Results show a practical path to evolve networks, enabling phased upgrades while maximizing fiber assets and avoiding service disruption Adtran today announced that TOHKnet has completed Japan’s first live network trial demonstrating the coexistence of 50G PON, XGS-PON and EPON on a single fiber. Conducted in Sendai using Adtran’s SDX 6400 Series OLT, the demo showed how the platform enables three generations of PON technology to operate together in a live service environment. The results highlight a realistic path for operators to introduce 50G PON capacity while maintaining continuity for existing services, maximizing the value of deployed fiber assets and reducing the complexity and disruption typically associated with network

Evexta Bio Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate Rupitasertib in Combination with a Selective Estrogen Receptor Degrader in Advanced / Metastatic Breast Cancer4.8.2026 09:00:00 CEST | Press release

Study to evaluate rupitasertib, Evexta Bio’s first-in-class oral dual-node, S6K and AKT1/3 inhibitor in combination with giredestrant in second-line ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer; expected to initiate in Q4 2026First clinical collaboration and supply agreement for Evexta Bio with rupitasertib and for Roche with giredestrant; results to inform future strategy for rupitasertib combination in ER+ HER2- advanced /metastatic breast cancer Evexta Bio S.A., a precision oncology company, founded by Truffle Capital (founder of Abivax and Carvolix), and focused on the discovery and development of targeted therapies, today announced a clinical collaboration and supply agreement with plans to initiate a Phase 1b study combining its lead investigational compound, rupitasertib, with Roche’s investigational compound giredestrant, a selective estrogen receptor degrader (SERD), for the treatment of ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer. Rupitasertib

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye